MMS Holdings Only Michigan Pharma Organization Awarded a 2022 Top Workplace USA Recognition

CANTON, Mich. (2/2/2022) – MMS Holdings, a data-focused clinical research organization, was recognized in the 2022 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates.  

 MMS, a minority and woman-owned business in Canton, was the only Michigan Pharma organization on the national list.  

 “We’re proud to represent Michigan Pharma organizations by being recognized as a Top Workplace, said Prasad M. Koppolu, Chief Operating Officer, MMS. “Our high retention rate and positive colleague culture enhance our mission of delivering high-quality service and technology solutions to assist clients in developing life-changing therapies.”  

 Winners of the Top Workplaces USA award are chosen based solely on employee feedback gathered through an employee engagement survey issued by Energage. Results are calculated by evaluating employee statements for culture drivers, such as innovation, inclusion, and alignment, that are proven to predict high performance.   

 “At MMS, we are focused on creating a culture of Diversity and Inclusion, Empathy, Professional Growth and Innovation to benefit our teams of colleagues around the world,” said Daria Fellrath, Senior Manager of Talent and Culture Management, MMS. “Fostering this culture is one of the top priorities of senior leadership and managers throughout our organization.” 

 Nearly 2,000 organizations were part of the national competition, which was based on regional winners.   

 “As a global organization of over 800 colleagues, our priority is maintaining alignment across four continents and cultivating #OneMMS culture in every colleague and team,” said Alan Nicolle, Senior Director of European and South African Operations, MMS. “A healthy workplace allows us to bring strong science and solutions to our clients.” 


MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.  

Media Contact 

Avery Zimmerman

Back to MMS News